查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1830983

發炎性腸道疾病治療市場

Inflammatory Bowel Disease Treatment Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

發炎性腸道疾病治療的市場價值預計將從 2024 年的 249.5 億美元增加到 2031 年的 316.7 億美元，2025 年至 2031 年期間的預估複合年成長率為 3.50%。

市場洞察與分析師觀點：發炎性腸道疾病 (IBD) 是指一種影響胃腸道的慢性發炎性疾病，包括克隆氏症和潰瘍性結腸炎等疾病。這些疾病會導致消化道內壁發炎，進而引發腹痛、腹瀉、疲勞和體重減輕等症狀。治療的目標是透過藥物治療、改變生活方式以及偶爾的手術來緩解發炎、控制症狀並避免併發症。持續的醫療照護和監測對於管理 IBD、維持緩解和提高生活品質至關重要。發炎性腸道疾病治療市場的成長主要得益於克隆氏症和潰瘍性結腸炎發病率的上升以及產品上市數量的增加。本報告概述了基於發炎性腸道疾病治療市場當前趨勢及其在預測期內的預期影響的成長機會。預計未來幾年，技術創新將為發炎性腸道疾病治療市場帶來重大趨勢。此外，透過持續研究和政府支持措施開發新的治療方法可能會進一步刺激市場成長。

成長因素與挑戰：克隆氏症是一種多方面的慢性疾病，主要影響消化系統。根據美國國家醫學圖書館的數據，2023年每10萬人中有825例發炎性腸道疾病（IBD），其中包括410例克隆氏症和414例潰瘍性結腸炎及IBD-u。 IBD的盛行率為0.82%，2023年約有322,600名加拿大人被診斷為IBD。由於診斷程序要求禁食、治療期間的飲食限制以及厭食或疾病本身引起的營養需求改變導致的食慾不振，胃腸道疾病患者面臨更高的營養不良風險。因此，腸內營養通常被推薦用於這些患者，因為它是輸送必需營養素的首選方法。因此，克隆氏症和潰瘍性結腸炎盛行率的不斷上升推動了發炎性腸道疾病治療市場的成長。

常見的胃腸道疾病包括克隆氏症、創傷性胃腸道疾病、腸阻塞（BO）、顯微鏡結腸炎、短腸症候群和潰瘍性結腸炎。 Healthline 2021年的一篇文章指出，全球約有40%的人口患有功能性胃腸道疾病。加拿大消化健康基金會報告稱，數百萬加拿大人患有消化系統疾病，每年約有2,000萬加拿大人（即每3人中就有2人）患有消化系統疾病。

相反，發炎性腸道疾病 (IBD) 治療的高昂費用給 IBD 治療市場帶來了重大挑戰。藥物、頻繁就診和手術相關的費用會給患者和醫療保健系統帶來沉重的經濟負擔。這一成本因素往往會限制許多 IBD 患者獲得最佳護理和創新治療的機會。解決可負擔性和可近性問題對於改善這種慢性疾病患者的治療效果和生活品質至關重要。因此，高昂的治療費用阻礙了發炎性腸道疾病治療市場的成長。

策略性洞察報告細分和範圍：發炎性腸道疾病治療市場的分析是透過檢查以下細分市場進行的：藥物類別、疾病適應症和配銷通路。從地理上講，發炎性腸道疾病治療市場分為北美（美國、加拿大和墨西哥）、歐洲（英國、德國、法國、義大利、西班牙和歐洲其他地區）、亞太地區（中國、日本、印度、澳洲、韓國和亞太其他地區）、中東和非洲（阿拉伯聯合大公國、沙烏地阿拉伯、南非和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷和南美洲和中美洲（巴西、阿根廷和南美洲和其他地區）。

細分分析：基於藥物類別的洞察。依藥物類別，市場分為生物製劑、氨基水楊酸鹽、皮質類固醇和其他藥物。生物製劑在2023年佔據了發炎性腸道疾病治療市場的最大佔有率，預計在2023年至2031年期間將呈現最高的複合年成長率。

基於疾病適應症的洞察：就疾病適應症而言，發炎性腸道疾病治療市場分為克隆氏症和潰瘍性結腸炎。預計到2031年，克隆氏症領域將佔據相當大的市場。

基於分銷管道的洞察：就分銷管道而言，市場分為醫院藥房、零售藥房和線上藥房。預計到2031年，醫院藥局將在發炎性腸道疾病治療市場中佔據相當大的佔有率。

發炎性腸道疾病治療市場報告範圍區域分析：發炎性腸道疾病治療市場報告的地理範圍包括北美、歐洲、亞太地區、中東和非洲以及南美和中美。 2023 年，北美佔據了最大的市場佔有率，美國憑藉其巨大的收入佔有率在該地區處於領先地位。美國發炎性腸道疾病治療市場的成長歸因於發炎性疾病的盛行率上升、主要市場參與者的存在及其策略性舉措。增強的支付解決方案、高治療率、創新藥物處方的增加、持續的研究努力以及有利的政府舉措也支持了美國和其他北美國家的發炎性腸道疾病治療市場。克隆氏症和結腸炎基金會是一個致力於推進旨在治療結腸炎和克隆氏症的臨床和轉化研究的著名組織。

競爭格局與關鍵公司：本報告中對發炎性腸道疾病治療市場的預測可以幫助利害關係人制定成長策略。發炎性腸道疾病治療市場報告中介紹的關鍵公司包括艾伯維公司、武田製藥有限公司、輝瑞公司、百健公司、諾華公司、禮來公司、優時比公司、CELLTRION公司、默克公司和強生服務公司。這些公司專注於擴大產品供應，以滿足日益成長的全球消費者需求。他們的國際影響力使他們能夠服務廣泛的客戶群，從而促進其市場擴張。

目錄

第1章：簡介

第 2 章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：發炎性腸道疾病治療市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表

第5章：發炎性腸道疾病治療市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：發炎性腸道疾病治療市場－全球市場分析

  • 發炎性腸道疾病治療－全球市場概覽
  • 發炎性腸道疾病治療－全球市場及2031年預測

第7章：發炎性腸道疾病治療市場 - 收入分析 - 按藥物類別，2021-2031 年

  • 概述
  • 氨基水楊酸鹽
  • 免疫調節劑
  • TNF抑制劑
  • 皮質類固醇

第 8 章：發炎性腸道疾病治療市場 - 收入分析 - 按疾病適應症，2021-2031 年

  • 概述
  • 克隆氏症
  • 潰瘍性結腸炎

第9章：發炎性腸道疾病治療市場-收入分析-按配銷通路，2021-2031

  • 概述
  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 10 章：發炎性腸道疾病治療市場 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 12 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 13 章：發炎性腸道疾病治療市場 - 主要公司簡介

  • Pfizer Inc.
  • Novartis AG
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Johnson and Johnson (Janssen Global Services, LLC)
  • CELGENE CORPORATION
  • Bausch Health Companies Inc.
  • UCB, Inc.
  • COSMO PHARMACEUTICALS
  • Gilead Sciences

第 14 章：附錄

簡介目錄
Product Code: TIPRE00003491

The market value for inflammatory bowel disease treatment is expected to increase from US$ 24.95 billion in 2024 to US$ 31.67 billion by 2031, with a projected CAGR of 3.50% during the period from 2025 to 2031.

Market Insights and Analyst Perspective:Inflammatory bowel disease (IBD) refers to a chronic inflammatory disorder affecting the gastrointestinal tract, which includes conditions such as Crohn's disease and ulcerative colitis. These diseases lead to inflammation of the digestive tract lining, resulting in symptoms like abdominal pain, diarrhea, fatigue, and weight loss. The goal of treatment is to alleviate inflammation, manage symptoms, and avert complications through medications, lifestyle modifications, and occasionally surgery. Ongoing medical care and monitoring are essential for managing IBD to maintain remission and enhance quality of life. The growth of the Inflammatory Bowel Disease Treatment Market is primarily driven by the increasing incidence of Crohn's disease and ulcerative colitis, along with a rise in product launches. This report outlines growth opportunities based on current trends in the Inflammatory Bowel Disease Treatment Market and their anticipated effects during the forecast period. Technological innovations are expected to introduce significant trends in the Inflammatory Bowel Disease Treatment Market in the upcoming years. Additionally, the development of new treatments through ongoing research and supportive government initiatives is likely to further stimulate market growth.

Growth Factors and Challenges:Crohn's disease is a multifaceted, chronic condition that mainly impacts the digestive system. According to the National Library of Medicine, there were 825 cases of IBD per 100,000 individuals in 2023, which includes 410 cases of Crohn's disease and 414 cases of ulcerative colitis and IBD-u. With a prevalence rate of 0.82%, approximately 322,600 Canadians were diagnosed with IBD in 2023. Patients suffering from gastrointestinal diseases face a heightened risk of nutritional decline due to the fasting requirements of diagnostic procedures, dietary restrictions for treatment, and appetite loss stemming from anorexia or altered nutritional needs caused by the disease itself. Consequently, enteral nutrition is often recommended for these patients, as it is the preferred method for delivering essential nutrients. Thus, the increasing prevalence of Crohn's disease and ulcerative colitis propels the growth of the Inflammatory Bowel Disease Treatment Market.

Common gastrointestinal diseases include Crohn's disease, trauma-related gastrointestinal disorders, bowel obstruction (BO), microscopic colitis, short bowel syndrome, and ulcerative colitis. An article published by Healthline in 2021 indicated that approximately 40% of the global population is affected by functional gastrointestinal disorders. The Canadian Digestive Health Foundation reports that millions of Canadians suffer from digestive diseases, with around 20 million Canadians, or 2 out of every 3 individuals, experiencing digestive disorders annually.

Conversely, the high costs associated with treating inflammatory bowel disease (IBD) present a significant challenge in the IBD treatment market. The expenses related to medications, frequent hospital visits, and surgeries can impose a substantial financial burden on patients and healthcare systems. This cost factor often restricts access to optimal care and innovative treatments for many individuals living with IBD. Addressing issues of affordability and accessibility is vital for enhancing outcomes and quality of life for patients affected by this chronic condition. Therefore, the high treatment costs impede the growth of the Inflammatory Bowel Disease Treatment Market.

Strategic Insights

Report Segmentation and Scope:The analysis of the Inflammatory Bowel Disease Treatment Market has been conducted by examining the following segments: drug class, disease indication, and distribution channel. Geographically, the Inflammatory Bowel Disease Treatment Market is divided into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:Insights Based on Drug ClassBy drug class, the market is categorized into biologics, aminosalicylates, corticosteroids, and others. The biologics segment accounted for the largest share of the Inflammatory Bowel Disease Treatment Market in 2023 and is expected to exhibit the highest CAGR from 2023 to 2031.

Insights Based on Disease IndicationIn terms of disease indication, the Inflammatory Bowel Disease Treatment Market is divided into Crohn's disease and ulcerative colitis. The Crohn's disease segment is projected to capture a significant market share by 2031.

Insights Based on Distribution Channel

Regarding distribution channels, the market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacy segment is expected to hold a substantial share of the Inflammatory Bowel Disease Treatment Market by 2031.

Inflammatory Bowel Disease Treatment Market Report ScopeRegional Analysis:The geographic scope of the Inflammatory Bowel Disease Treatment Market report includes North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. In 2023, North America held the largest market share, with the US leading the market in this region due to its significant revenue share. The growth of the Inflammatory Bowel Disease Treatment Market in the US is attributed to the rising prevalence of inflammatory diseases, the presence of major market players, and their strategic initiatives. Enhanced payment solutions, high treatment rates, increased prescriptions of innovative medications, continuous research efforts, and favorable government initiatives also support the Inflammatory Bowel Disease Treatment Market in the US and other North American countries. The Crohn's & Colitis Foundation is a prominent organization dedicated to advancing clinical and translational research aimed at curing colitis and Crohn's disease.

Competitive Landscape and Key Companies:The forecast for the Inflammatory Bowel Disease Treatment Market presented in this report can assist stakeholders in formulating their growth strategies. Key companies profiled in the Inflammatory Bowel Disease Treatment Market report include AbbVie Inc, Takeda Pharmaceutical Company Limited, Pfizer Inc, Biogen, Novartis AG, Lilly, UCB S.A., CELLTRION INC., Merck & Co., Inc., and Johnson & Johnson Services, Inc. These companies are focused on expanding their product offerings to meet the growing global consumer demand. Their international presence enables them to serve a wide customer base, thereby facilitating their market expansion.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Inflammatory Bowel Disease Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Inflammatory Bowel Disease Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Inflammatory Bowel Disease Treatment Market - Global Market Analysis

  • 6.1 Inflammatory Bowel Disease Treatment - Global Market Overview
  • 6.2 Inflammatory Bowel Disease Treatment - Global Market and Forecast to 2031

7. Inflammatory Bowel Disease Treatment Market - Revenue Analysis (USD Million) - By Drug Class, 2021-2031

  • 7.1 Overview
  • 7.2 Aminosalicyclates
  • 7.3 Immunomodulators
  • 7.4 TNF Inhibitors
  • 7.5 Corticosteroids

8. Inflammatory Bowel Disease Treatment Market - Revenue Analysis (USD Million) - By Disease Indication, 2021-2031

  • 8.1 Overview
  • 8.2 Crohn's Disease
  • 8.3 Ulcerative Colitis

9. Inflammatory Bowel Disease Treatment Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 9.1 Overview
  • 9.2 Hospital Pharmacy
  • 9.3 Online Pharmacy
  • 9.4 Retail Pharmacy

10. Inflammatory Bowel Disease Treatment Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Inflammatory Bowel Disease Treatment Market Overview
    • 10.1.2 North America Inflammatory Bowel Disease Treatment Market Revenue and Forecasts to 2031
    • 10.1.3 North America Inflammatory Bowel Disease Treatment Market Revenue and Forecasts and Analysis - By Drug Class
    • 10.1.4 North America Inflammatory Bowel Disease Treatment Market Revenue and Forecasts and Analysis - By Disease Indication
    • 10.1.5 North America Inflammatory Bowel Disease Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 10.1.6 North America Inflammatory Bowel Disease Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Inflammatory Bowel Disease Treatment Market
        • 10.1.6.1.1 United States Inflammatory Bowel Disease Treatment Market, by Drug Class
        • 10.1.6.1.2 United States Inflammatory Bowel Disease Treatment Market, by Disease Indication
        • 10.1.6.1.3 United States Inflammatory Bowel Disease Treatment Market, by Distribution Channel
      • 10.1.6.2 Canada Inflammatory Bowel Disease Treatment Market
        • 10.1.6.2.1 Canada Inflammatory Bowel Disease Treatment Market, by Drug Class
        • 10.1.6.2.2 Canada Inflammatory Bowel Disease Treatment Market, by Disease Indication
        • 10.1.6.2.3 Canada Inflammatory Bowel Disease Treatment Market, by Distribution Channel
      • 10.1.6.3 Mexico Inflammatory Bowel Disease Treatment Market
        • 10.1.6.3.1 Mexico Inflammatory Bowel Disease Treatment Market, by Drug Class
        • 10.1.6.3.2 Mexico Inflammatory Bowel Disease Treatment Market, by Disease Indication
        • 10.1.6.3.3 Mexico Inflammatory Bowel Disease Treatment Market, by Distribution Channel
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Inflammatory Bowel Disease Treatment Market - Key Company Profiles

  • 13.1 Pfizer Inc.
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Novartis AG
  • 13.3 AbbVie Inc.
  • 13.4 Takeda Pharmaceutical Company Limited
  • 13.5 Johnson and Johnson (Janssen Global Services, LLC)
  • 13.6 CELGENE CORPORATION
  • 13.7 Bausch Health Companies Inc.
  • 13.8 UCB, Inc.
  • 13.9 COSMO PHARMACEUTICALS
  • 13.10 Gilead Sciences

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud